The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
PGC1β Mediates PPARγ Activation of Osteoclastogenesis and Rosiglitazone-Induced Bone Loss
Open accessAbstract
SUMMARY Long-term usage of rosiglitazone, a synthetic PPARγ agonist, increases fracture rates among diabetic patients. PPARγ suppresses osteoblastogenesis while activating osteoclastogenesis, suggesting that rosiglitazone decreases bone formation while sustaining or increasing bone resorption. Using mouse models with genetically altered PPARγ, PGC1β or ERRα, here we show that PGC1β is required for the resorption-enhancing effects of rosiglitazone. PPARγ activation indirectly induces PGC1β expression by down-regulating β-catenin and derepressing c-jun. PGC1β in turn functions as a PPARγ coactivator to stimulate osteoclast differentiation. Complementarily, PPARγ also induces ERRα expression, which coordinates with PGC1β to enhance mitochondrial biogenesis and osteoclast function. ERRα knockout mice exhibit osteoclast defects, revealing ERRα as an important regulator of osteoclastogenesis. Strikingly, PGC1β deletion in osteoclasts confers complete resistance to rosiglitazone-induced bone loss. These findings identify PGC1β as an essential mediator for the PPARγ stimulation of osteoclastogenesis by targeting both PPARγ itself and ERRα, thus activating two distinct transcriptional programs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation
Ricote, M., Li, A. C., Willson, T. M., Kelly, C. J., & Glass, C. K. (1998) · Nature · doi:10.1038/34178 · Cited by 3,525
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
Fat and Beyond: The Diverse Biology of PPARγ
Tontonoz, P., & Spiegelman, B. M. (2008) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.77.061307.091829 · Cited by 2,085
Barroso, I., Gurnell, M., Crowley, V. E. F., Agostini, M., Schwabe, J. W., Soos, M. A., Maslen, G. L., Williams, T. D. M., Lewis, H., Schafer, A. J., et al. (1999) · Nature · doi:10.1038/47254 · Cited by 1,368
A PPARγ-LXR-ABCA1 Pathway in Macrophages Is Involved in Cholesterol Efflux and Atherogenesis
Chawla, A., Boisvert, W. A., Lee, C.-H., Laffitte, B. A., Barak, Y., Joseph, S. B., Liao, D., Nagy, L., Edwards, P. A., Curtiss, L. K., et al. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00164-2 · Cited by 1,347
Tie2-Cre Transgenic Mice: A New Model for Endothelial Cell-Lineage Analysis in Vivo
Kisanuki, Y. Y., Hammer, R. E., Miyazaki, J.-I., Williams, S. C., Richardson, J. A., & Yanagisawa, M. (2001) · Developmental Biology · doi:10.1006/dbio.2000.0106 · Cited by 1,241
Rosiglitazone-Associated Fractures in Type 2 Diabetes
Kahn, S. E., Zinman, B., Lachin, J. M., Haffner, S. M., Herman, W. H., Holman, R. R., Kravitz, B. G., Yu, D., Heise, M. A., Aftring, R. P., et al. (2008) · Diabetes Care · doi:10.2337/dc07-2270 · Cited by 537
Coordination of PGC-1β and iron uptake in mitochondrial biogenesis and osteoclast activation
Ishii, K.-A., Fumoto, T., Iwai, K., Takeshita, S., Ito, M., Shimohata, N., Aburatani, H., Taketani, S., Lelliott, C. J., Vidal-Puig, A., et al. (2009) · Nature Medicine · doi:10.1038/nm.1910 · Cited by 410 · cited 5×
“, 2010); conversely, transcription factors activated during osteoclast differentiation induce target gene expression to promote osteoclast function and mitochondrial biogenesis (Ishii et al., 2009; Novack and Teitelbaum, 2008).”
BackgroundInfluentialReduced fat mass in mice lacking orphan nuclear receptor estrogen-related receptor α.
Luo, J., Sladek, R., Carrier, J., Bader, J.-A., Richard, D., & Giguère, V. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.22.7947-7956.2003 · Cited by 370 · cited 2×
“, 2007b), ERRa KO mice (Luo et al., 2003), and b-catenin mice (Brault et al.”
BackgroundKamei, Y., Ohizumi, H., Fujitani, Y., Nemoto, T., Tanaka, T., Takahashi, N., Kawada, T., Miyoshi, M., Ezaki, O., & Kakizuka, A. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2135217100 · Cited by 357
Cited by
Osteoimmunology: The conceptual framework unifying the immune and skeletal systems
Okamoto, K., Nakashima, T., Shinohara, M., Negishi-Koga, T., Komatsu, N., Terashima, A., Sawa, S., Nitta, T., & Takayanagi, H. (2017) · Physiological Reviews · doi:10.1152/physrev.00036.2016 · Cited by 534
Wei, W., Dutchak, P. A., Wang, X., Ding, X., Wang, X., Bookout, A. L., Goetz, R., Mohammadi, M., Gerard, R. D., Dechow, P. C., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1200797109 · Cited by 426
Self-citationPGC-1 Coactivators in Cardiac Development and Disease
Rowe, G. C., Jiang, A., & Arany, Z. (2010) · Circulation Research · doi:10.1161/circresaha.110.223818 · Cited by 355
PPARγ: a circadian transcription factor in adipogenesis and osteogenesis
Kawai, M., & Rosen, C. J. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.155 · Cited by 323
Krzeszinski, J. Y., Wei, W., Huynh, H., Jin, Z., Wang, X., Chang, T.-C., Xie, X.-J., He, L., Mangala, L. S., Lopez-Berestein, G., et al. (2014) · Nature · doi:10.1038/nature13375 · Cited by 303
Self-citationRetractedOsteopontin in Bone Metabolism and Bone Diseases
Si, J., Wang, C., Zhang, D., Wang, B., Hou, W., & Zhou, Y. (2020) · Medical Science Monitor · doi:10.12659/msm.919159 · Cited by 301
Molecular Mechanisms and Emerging Therapeutics for Osteoporosis
Noh, J.-Y., Yang, Y., & Jung, H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207623 · Cited by 287
Jin, Z., Wei, W., Yang, M., Du, Y., & Wan, Y. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.07.011 · Cited by 283
Self-citationNew insights into osteoporosis: the bone–fat connection
Kawai, M., de Paula, F. J. A., & Rosen, C. J. (2012) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2012.02564.x · Cited by 273
Wang, X., Wei, W., Krzeszinski, J. Y., Wang, Y., & Wan, Y. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.09.010 · Cited by 165
Defects in a liver-bone axis contribute to hepatic osteodystrophy disease progression
Lu, K., Shi, T.-S., Shen, S.-Y., Shi, Y., Gao, H.-L., Wu, J., Lu, X., Gao, X., Ju, H.-X., Wang, W., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.02.006 · Cited by 126
Zhou, J., Ye, S., Fujiwara, T., Manolagas, S. C., & Zhao, H. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.478750 · Cited by 88
Izawa, T., Arakaki, R., Mori, H., Tsunematsu, T., Kudo, Y., Tanaka, E., & Ishimaru, N. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1600822 · Cited by 64
Tang, W., Ding, Z., Gao, H., Yan, Q., Liu, J., Han, Y., Hou, X., Liu, Z., Chen, L., Yang, D., et al. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.07.001 · Cited by 35
“Therefore, we administered 3-month-old mice with rosiglitazone (30 mg/kg/day) or vehicle (1% carboxy-methylcellulose in saline) daily, by oral gavage for 1 month 66,67 .”
MethodRaimondi, V., Toscani, D., Marchica, V., Burroughs-Garcia, J., Storti, P., & Giuliani, N. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1015402 · Cited by 10
Metadata
- Authors
- Wei, W., Wang, X., Yang, M., Smith, L. C., Dechow, P. C., & Wan, Y.
- Venue
- Cell Metabolism
- Publisher
- Elsevier BV
- Published
- 2010-06
- Volume
- 11
- Issue
- 6
- Pages
- 503-516
- ISSN
- 1550-4131 (ISSN-L)
- OpenAlex
- W2145968349
- Cited by
- 243
- References
- 14
- FWCI
- 5.79
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.